Filing Overview
Registrant: NLS Pharmaceutics Ltd. The supplied metadata identifies Newcelx Ltd., but the filing names NLS Pharmaceutics Ltd. as the registrant.
Form and period: Form 6-K covering March 2021; filed March 1, 2021. Commission file number 001-39957. The company files annual reports on Form 20-F.
Material Corporate Change
- Pascal Brenneisen resigned from the board of directors effective February 28, 2021.
- The filing states that the resignation was for personal reasons and was not related to any disagreement with the company.
- Following the resignation, the company was no longer in compliance with Nasdaq Listing Rule 5605(c)(2), which requires an audit committee with at least three independent members.
- The board planned an immediate search for a qualified replacement and expected the replacement to be elected by shareholders and appointed to the audit committee within the Nasdaq cure period.
Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other financial operating metrics.
Outlook, Risks, and Contingencies
- The principal disclosed risk is potential noncompliance with Nasdaq’s audit committee composition requirement.
- Management expected to use the applicable Nasdaq cure period to restore compliance, but the filing does not specify the deadline or any consequences if compliance was not achieved.
Investor Verification Items
- Confirm the registrant’s identity, because the request metadata names Newcelx Ltd. while the filing names NLS Pharmaceutics Ltd.
- Verify whether a replacement director was elected and appointed to the audit committee within the Nasdaq cure period.
- Confirm the company’s subsequent Nasdaq listing status and audit committee composition.
- Review later filings for any additional board changes or related compliance disclosures.